China-based nucleic acid-based therapeutics developer RongCan (Shanghai) Biotech Co., Ltd has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round led by a “reputational healthcare fund.” The proceeds will be used to accelerate product research and development (R&D), team building, and clinical studies for leading pipelines.
Company Profile
Founded in 2020, RongCan Bio has established a comprehensive R&D system covering mRNA sequence design and synthesis, lipid chemistry, LNP preparation R&D, amplification process, analytical method development, validation, and biological evaluation. The company’s GMP-compliant mRNA stock solution and LNP preparation pilot production line enable the manufacturing of samples from the investigational new drug (IND) to clinical phase I-II stages. This robust infrastructure positions RongCan Bio to advance its innovative mRNA therapeutics.
Future Plans
With the new funding, RongCan Bio plans to enhance its R&D capabilities, build a stronger team, and progress its leading pipelines through clinical studies. This strategic move aims to solidify the company’s position in the rapidly growing field of nucleic acid-based therapeutics, offering potential treatments for a range of diseases.-Fineline Info & Tech
